ID   BRPF1_HUMAN             Reviewed;        1214 AA.
AC   P55201; B4DEZ6; Q7Z6E0; Q8TCM6; Q9UHI0;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   10-MAY-2017, entry version 160.
DE   RecName: Full=Peregrin {ECO:0000305};
DE   AltName: Full=Bromodomain and PHD finger-containing protein 1 {ECO:0000312|HGNC:HGNC:14255};
DE   AltName: Full=Protein Br140 {ECO:0000303|PubMed:7906940};
GN   Name=BRPF1 {ECO:0000312|HGNC:HGNC:14255};
GN   Synonyms=BR140 {ECO:0000303|PubMed:7906940};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RX   PubMed=7906940; DOI=10.1006/bbrc.1994.1162;
RA   Thompson K.A., Wang B., Argraves W.S., Giancotti F.G., Schranck D.P.,
RA   Ruoslahti E.;
RT   "BR140, a novel zinc-finger protein with homology to the TAF250
RT   subunit of TFIID.";
RL   Biochem. Biophys. Res. Commun. 198:1143-1152(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Hu S.N., Dong W., Zeng Y.X., Yu J., Yang H.M.;
RT   "Sequencing and analyzing of BAC DNA on 3p26.";
RL   Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-460 AND SER-462, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   FUNCTION, AND IDENTIFICATION IN THE MOZ/MORF COMPLEX.
RX   PubMed=16387653; DOI=10.1016/j.molcel.2005.12.007;
RA   Doyon Y., Cayrou C., Ullah M., Landry A.-J., Cote V., Selleck W.,
RA   Lane W.S., Tan S., Yang X.-J., Cote J.;
RT   "ING tumor suppressor proteins are critical regulators of chromatin
RT   acetylation required for genome expression and perpetuation.";
RL   Mol. Cell 21:51-64(2006).
RN   [10]
RP   FUNCTION, IDENTIFICATION IN THE MOZ/MORF COMPLEX, INTERACTION WITH
RP   ING5; MEAF6; KAT6A AND KAT6B, SUBCELLULAR LOCATION, AND ACETYLATION.
RX   PubMed=18794358; DOI=10.1128/MCB.01297-08;
RA   Ullah M., Pelletier N., Xiao L., Zhao S.P., Wang K., Degerny C.,
RA   Tahmasebi S., Cayrou C., Doyon Y., Goh S.-L., Champagne N., Cote J.,
RA   Yang X.-J.;
RT   "Molecular architecture of quartet MOZ/MORF histone acetyltransferase
RT   complexes.";
RL   Mol. Cell. Biol. 28:6828-6843(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-120 AND SER-1187, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1076, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-460; SER-462 AND
RP   SER-1076, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-460; SER-462; SER-860
RP   AND SER-1076, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-460 AND SER-462, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-238, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   STRUCTURE BY NMR OF 633-740.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the bromodomain of peregrin.";
RL   Submitted (JUN-2006) to the PDB data bank.
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 1076-1205 IN COMPLEX WITH
RP   HISTONE H3 PEPTIDE, AND INTERACTION WITH HISTONE H3.
RX   PubMed=20400950; DOI=10.1038/nsmb.1797;
RA   Vezzoli A., Bonadies N., Allen M.D., Freund S.M., Santiveri C.M.,
RA   Kvinlaug B.T., Huntly B.J., Gottgens B., Bycroft M.;
RT   "Molecular basis of histone H3K36me3 recognition by the PWWP domain of
RT   Brpf1.";
RL   Nat. Struct. Mol. Biol. 17:617-619(2010).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.3 ANGSTROMS) OF 1079-1207 IN COMPLEX WITH
RP   TRIMETHYLATED HISTONE H3 PEPTIDE, AND INTERACTION WITH HISTONE H3.
RX   PubMed=21720545; DOI=10.1371/journal.pone.0018919;
RA   Wu H., Zeng H., Lam R., Tempel W., Amaya M.F., Xu C., Dombrovski L.,
RA   Qiu W., Wang Y., Min J.;
RT   "Structural and histone binding ability characterizations of human
RT   PWWP domains.";
RL   PLoS ONE 6:E18919-E18919(2011).
RN   [21]
RP   INVOLVEMENT IN IDDDFP, VARIANTS IDDDFP SER-370; 455-ARG--ASP-1214 DEL;
RP   833-GLY--ASP-1214 DEL AND 1100-PRO--ASP-1214 DEL, CHARACTERIZATION OF
RP   VARIANTS IDDDFP SER-370; 455-ARG--ASP-1214 DEL; 833-GLY--ASP-1214 DEL
RP   AND 1100-PRO--ASP-1214 DEL, FUNCTION, SUBUNIT, INTERACTION WITH KAT7,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=27939640; DOI=10.1016/j.ajhg.2016.11.011;
RG   DDD Study;
RG   CAUSES Study;
RA   Yan K., Rousseau J., Littlejohn R.O., Kiss C., Lehman A.,
RA   Rosenfeld J.A., Stumpel C.T., Stegmann A.P., Robak L., Scaglia F.,
RA   Nguyen T.T., Fu H., Ajeawung N.F., Camurri M.V., Li L., Gardham A.,
RA   Panis B., Almannai M., Sacoto M.J., Baskin B., Ruivenkamp C., Xia F.,
RA   Bi W., Cho M.T., Potjer T.P., Santen G.W., Parker M.J., Canham N.,
RA   McKinnon M., Potocki L., MacKenzie J.J., Roeder E.R., Campeau P.M.,
RA   Yang X.J.;
RT   "Mutations in the chromatin regulator gene BRPF1 cause syndromic
RT   intellectual disability and deficient histone acetylation.";
RL   Am. J. Hum. Genet. 100:91-104(2017).
RN   [22]
RP   INVOLVEMENT IN IDDDFP, AND VARIANTS IDDDFP 35-TYR--ASP-1214 DEL;
RP   ARG-389 AND 988-LEU--ASP-1214 DEL.
RX   PubMed=27939639; DOI=10.1016/j.ajhg.2016.11.010;
RA   Mattioli F., Schaefer E., Magee A., Mark P., Mancini G.M.,
RA   Dieterich K., Von Allmen G., Alders M., Coutton C.,
RA   van Slegtenhorst M., Vieville G., Engelen M., Cobben J.M., Juusola J.,
RA   Pujol A., Mandel J.L., Piton A.;
RT   "Mutations in histone acetylase modifier BRPF1 cause an autosomal-
RT   dominant form of intellectual disability with associated ptosis.";
RL   Am. J. Hum. Genet. 100:105-116(2017).
CC   -!- FUNCTION: Component of the MOZ/MORF complex which has a histone H3
CC       acetyltransferase activity (PubMed:16387653, PubMed:27939640).
CC       Preferentially mediates histone H3-K23 acetylation
CC       (PubMed:27939640). Positively regulates the transcription of RUNX1
CC       and RUNX2 (PubMed:18794358). {ECO:0000269|PubMed:16387653,
CC       ECO:0000269|PubMed:18794358, ECO:0000269|PubMed:27939640}.
CC   -!- SUBUNIT: Component of the MOZ/MORF complex composed at least of
CC       ING5, KAT6A, KAT6B, MEAF6 and one of BRPF1, BRD1/BRPF2 and BRPF3
CC       (PubMed:16387653, PubMed:18794358, PubMed:27939640). Interacts
CC       with trimethylated 'Lys-36' of histone H3 (H3K36me3)
CC       (PubMed:20400950, PubMed:21720545). May interact with KAT7
CC       (PubMed:27939640). {ECO:0000269|PubMed:16387653,
CC       ECO:0000269|PubMed:18794358, ECO:0000269|PubMed:20400950,
CC       ECO:0000269|PubMed:21720545, ECO:0000269|PubMed:27939640}.
CC   -!- INTERACTION:
CC       P0C0S8:HIST1H2AM; NbExp=8; IntAct=EBI-2837428, EBI-1390628;
CC       P62805:HIST2H4B; NbExp=8; IntAct=EBI-2837428, EBI-302023;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:18794358,
CC       ECO:0000269|PubMed:27939640}. Cytoplasm
CC       {ECO:0000269|PubMed:18794358, ECO:0000269|PubMed:27939640}.
CC       Note=Localization to the nucleus depends on KAT6A, ING5 and MEAF6.
CC       {ECO:0000269|PubMed:18794358, ECO:0000269|PubMed:27939640}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P55201-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P55201-2; Sequence=VSP_037955;
CC       Name=3;
CC         IsoId=P55201-3; Sequence=VSP_037956;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=P55201-4; Sequence=VSP_037957;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: High levels in testis.
CC       {ECO:0000269|PubMed:7906940}.
CC   -!- PTM: Acetylated by KAT6A. {ECO:0000269|PubMed:18794358}.
CC   -!- DISEASE: Intellectual developmental disorder with dysmorphic
CC       facies and ptosis (IDDDFP) [MIM:617333]: An autosomal dominant
CC       neurodevelopmental disorder characterized by delayed psychomotor
CC       development, intellectual disability, delayed language, and facial
CC       dysmorphisms, most notably ptosis. Additional features may include
CC       poor growth, hypotonia, and seizures.
CC       {ECO:0000269|PubMed:27939639, ECO:0000269|PubMed:27939640}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M91585; AAB02119.1; -; mRNA.
DR   EMBL; AF176815; AAF19605.1; -; Genomic_DNA.
DR   EMBL; AK293865; BAG57257.1; -; mRNA.
DR   EMBL; AL713696; CAD28495.1; -; mRNA.
DR   EMBL; AC022382; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471055; EAW63976.1; -; Genomic_DNA.
DR   EMBL; BC053851; AAH53851.1; -; mRNA.
DR   CCDS; CCDS2575.1; -. [P55201-1]
DR   CCDS; CCDS33692.1; -. [P55201-2]
DR   CCDS; CCDS82729.1; -. [P55201-4]
DR   CCDS; CCDS82730.1; -. [P55201-3]
DR   PIR; JC2069; JC2069.
DR   RefSeq; NP_001003694.1; NM_001003694.1. [P55201-2]
DR   RefSeq; NP_001305978.1; NM_001319049.1. [P55201-4]
DR   RefSeq; NP_001305979.1; NM_001319050.1. [P55201-3]
DR   RefSeq; NP_004625.2; NM_004634.2. [P55201-1]
DR   UniGene; Hs.1004; -.
DR   PDB; 2D9E; NMR; -; A=633-740.
DR   PDB; 2RS9; NMR; -; B=633-740.
DR   PDB; 2X35; X-ray; 2.00 A; A=1076-1205.
DR   PDB; 2X4W; X-ray; 1.50 A; A=1076-1205.
DR   PDB; 2X4X; X-ray; 1.85 A; A/C/E/G=1076-1205.
DR   PDB; 2X4Y; X-ray; 1.70 A; A/C/E/G/I/K/M/O=1076-1205.
DR   PDB; 3L42; X-ray; 1.30 A; A=1079-1207.
DR   PDB; 3MO8; X-ray; 1.69 A; A=1079-1207.
DR   PDB; 4LC2; X-ray; 1.65 A; A=626-740.
DR   PDB; 4QYD; X-ray; 1.94 A; A=629-742.
DR   PDB; 4QYL; X-ray; 1.80 A; A/B/C/D=629-742.
DR   PDB; 4UYE; X-ray; 1.65 A; A/B=622-738.
DR   PDB; 5C6S; X-ray; 1.30 A; A=1079-1207.
DR   PDB; 5C7N; X-ray; 1.75 A; A=626-740.
DR   PDB; 5C85; X-ray; 1.70 A; A=626-740.
DR   PDB; 5C87; X-ray; 1.55 A; A=626-740.
DR   PDB; 5C89; X-ray; 1.65 A; A=627-740.
DR   PDB; 5D7X; X-ray; 1.35 A; A=626-740.
DR   PDB; 5DY7; X-ray; 1.69 A; A=626-740.
DR   PDB; 5DYA; X-ray; 1.65 A; A=626-740.
DR   PDB; 5DYC; X-ray; 1.65 A; A=626-740.
DR   PDB; 5E3D; X-ray; 1.71 A; A=626-740.
DR   PDB; 5E3G; X-ray; 1.65 A; A=626-740.
DR   PDB; 5EM3; X-ray; 1.40 A; A=626-740.
DR   PDB; 5EPR; X-ray; 1.65 A; A=626-740.
DR   PDB; 5EPS; X-ray; 1.47 A; A=627-740.
DR   PDB; 5EQ1; X-ray; 1.55 A; A=626-740.
DR   PDB; 5ERC; X-ray; 2.05 A; A=274-450.
DR   PDB; 5ETB; X-ray; 1.33 A; A=626-740.
DR   PDB; 5ETD; X-ray; 1.40 A; A=626-740.
DR   PDB; 5EV9; X-ray; 1.45 A; A=626-740.
DR   PDB; 5EVA; X-ray; 1.45 A; A=626-740.
DR   PDB; 5EWC; X-ray; 1.75 A; A=626-740.
DR   PDB; 5EWD; X-ray; 1.58 A; A=626-740.
DR   PDB; 5EWH; X-ray; 1.63 A; A=626-740.
DR   PDB; 5EWV; X-ray; 1.67 A; A=626-740.
DR   PDB; 5EWW; X-ray; 1.73 A; A=626-740.
DR   PDB; 5FFV; X-ray; 1.30 A; A/B=626-740.
DR   PDB; 5FFW; X-ray; 1.50 A; A/B=626-740.
DR   PDB; 5FFY; X-ray; 1.55 A; A=626-740.
DR   PDB; 5FG4; X-ray; 1.65 A; A=626-740.
DR   PDB; 5FG5; X-ray; 1.50 A; A/B=626-740.
DR   PDB; 5G4R; X-ray; 1.96 A; A/B/C/D=622-738.
DR   PDB; 5G4S; X-ray; 1.60 A; A=624-738.
DR   PDB; 5T4U; X-ray; 1.50 A; A=627-740.
DR   PDB; 5T4V; X-ray; 1.65 A; A=627-740.
DR   PDBsum; 2D9E; -.
DR   PDBsum; 2RS9; -.
DR   PDBsum; 2X35; -.
DR   PDBsum; 2X4W; -.
DR   PDBsum; 2X4X; -.
DR   PDBsum; 2X4Y; -.
DR   PDBsum; 3L42; -.
DR   PDBsum; 3MO8; -.
DR   PDBsum; 4LC2; -.
DR   PDBsum; 4QYD; -.
DR   PDBsum; 4QYL; -.
DR   PDBsum; 4UYE; -.
DR   PDBsum; 5C6S; -.
DR   PDBsum; 5C7N; -.
DR   PDBsum; 5C85; -.
DR   PDBsum; 5C87; -.
DR   PDBsum; 5C89; -.
DR   PDBsum; 5D7X; -.
DR   PDBsum; 5DY7; -.
DR   PDBsum; 5DYA; -.
DR   PDBsum; 5DYC; -.
DR   PDBsum; 5E3D; -.
DR   PDBsum; 5E3G; -.
DR   PDBsum; 5EM3; -.
DR   PDBsum; 5EPR; -.
DR   PDBsum; 5EPS; -.
DR   PDBsum; 5EQ1; -.
DR   PDBsum; 5ERC; -.
DR   PDBsum; 5ETB; -.
DR   PDBsum; 5ETD; -.
DR   PDBsum; 5EV9; -.
DR   PDBsum; 5EVA; -.
DR   PDBsum; 5EWC; -.
DR   PDBsum; 5EWD; -.
DR   PDBsum; 5EWH; -.
DR   PDBsum; 5EWV; -.
DR   PDBsum; 5EWW; -.
DR   PDBsum; 5FFV; -.
DR   PDBsum; 5FFW; -.
DR   PDBsum; 5FFY; -.
DR   PDBsum; 5FG4; -.
DR   PDBsum; 5FG5; -.
DR   PDBsum; 5G4R; -.
DR   PDBsum; 5G4S; -.
DR   PDBsum; 5T4U; -.
DR   PDBsum; 5T4V; -.
DR   ProteinModelPortal; P55201; -.
DR   SMR; P55201; -.
DR   BioGrid; 113614; 24.
DR   DIP; DIP-59001N; -.
DR   IntAct; P55201; 25.
DR   STRING; 9606.ENSP00000373340; -.
DR   BindingDB; P55201; -.
DR   ChEMBL; CHEMBL3132741; -.
DR   GuidetoPHARMACOLOGY; 2730; -.
DR   iPTMnet; P55201; -.
DR   PhosphoSitePlus; P55201; -.
DR   BioMuta; BRPF1; -.
DR   DMDM; 116241271; -.
DR   EPD; P55201; -.
DR   MaxQB; P55201; -.
DR   PaxDb; P55201; -.
DR   PeptideAtlas; P55201; -.
DR   PRIDE; P55201; -.
DR   TopDownProteomics; P55201-2; -. [P55201-2]
DR   Ensembl; ENST00000383829; ENSP00000373340; ENSG00000156983. [P55201-2]
DR   Ensembl; ENST00000424362; ENSP00000398863; ENSG00000156983. [P55201-3]
DR   Ensembl; ENST00000433861; ENSP00000402485; ENSG00000156983. [P55201-4]
DR   Ensembl; ENST00000457855; ENSP00000410210; ENSG00000156983. [P55201-1]
DR   GeneID; 7862; -.
DR   KEGG; hsa:7862; -.
DR   UCSC; uc003bsf.4; human. [P55201-1]
DR   CTD; 7862; -.
DR   DisGeNET; 7862; -.
DR   GeneCards; BRPF1; -.
DR   HGNC; HGNC:14255; BRPF1.
DR   HPA; HPA003359; -.
DR   MIM; 602410; gene.
DR   MIM; 617333; phenotype.
DR   neXtProt; NX_P55201; -.
DR   OpenTargets; ENSG00000156983; -.
DR   PharmGKB; PA25424; -.
DR   eggNOG; KOG0955; Eukaryota.
DR   eggNOG; COG5141; LUCA.
DR   GeneTree; ENSGT00740000114866; -.
DR   HOGENOM; HOG000000705; -.
DR   HOVERGEN; HBG004895; -.
DR   InParanoid; P55201; -.
DR   KO; K11348; -.
DR   OMA; SPSREVM; -.
DR   OrthoDB; EOG091G00VK; -.
DR   PhylomeDB; P55201; -.
DR   TreeFam; TF316118; -.
DR   Reactome; R-HSA-3214847; HATs acetylate histones.
DR   Reactome; R-HSA-6804758; Regulation of TP53 Activity through Acetylation.
DR   ChiTaRS; BRPF1; human.
DR   EvolutionaryTrace; P55201; -.
DR   GenomeRNAi; 7862; -.
DR   PRO; PR:P55201; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000156983; -.
DR   CleanEx; HS_BRPF1; -.
DR   ExpressionAtlas; P55201; baseline and differential.
DR   Genevisible; P55201; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070776; C:MOZ/MORF histone acetyltransferase complex; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0043966; P:histone H3 acetylation; IDA:UniProtKB.
DR   GO; GO:0043972; P:histone H3-K23 acetylation; IMP:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 1.20.920.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 2.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR019542; Enhancer_polycomb-like_N.
DR   InterPro; IPR034732; EPHD.
DR   InterPro; IPR000313; PWWP_dom.
DR   InterPro; IPR019786; Zinc_finger_PHD-type_CS.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   Pfam; PF00439; Bromodomain; 1.
DR   Pfam; PF10513; EPL1; 1.
DR   Pfam; PF00855; PWWP; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM00249; PHD; 2.
DR   SMART; SM00293; PWWP; 1.
DR   SUPFAM; SSF47370; SSF47370; 1.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   PROSITE; PS00633; BROMODOMAIN_1; 1.
DR   PROSITE; PS50014; BROMODOMAIN_2; 1.
DR   PROSITE; PS51805; EPHD; 1.
DR   PROSITE; PS50812; PWWP; 1.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 1.
DR   PROSITE; PS50157; ZINC_FINGER_C2H2_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   Bromodomain; Chromatin regulator; Complete proteome; Cytoplasm;
KW   Disease mutation; DNA-binding; Mental retardation; Metal-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Transcription; Transcription regulation; Zinc; Zinc-finger.
FT   CHAIN         1   1214       Peregrin.
FT                                /FTId=PRO_0000211187.
FT   DOMAIN      645    715       Bromo. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00035}.
FT   DOMAIN     1085   1168       PWWP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00162}.
FT   ZN_FING      21     47       C2H2-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00042}.
FT   ZN_FING     273    323       PHD-type 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00146}.
FT   ZN_FING     327    360       C2HC pre-PHD-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01146}.
FT   ZN_FING     384    448       PHD-type 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01146}.
FT   REGION       59    222       Interaction with KAT6A and KAT6B.
FT                                {ECO:0000269|PubMed:18794358}.
FT   REGION      501    821       Interaction with MEAF6 and ING5.
FT                                {ECO:0000269|PubMed:18794358}.
FT   REGION      543   1079       Required for RUNX1 and RUNX2
FT                                transcriptional activation.
FT   MOD_RES     120    120       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     238    238       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     460    460       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     462    462       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     860    860       Phosphoserine.
FT                                {ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1076   1076       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1187   1187       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   VAR_SEQ     660    660       S -> SEVTELD (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_037955.
FT   VAR_SEQ     765    765       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:17974005}.
FT                                /FTId=VSP_037956.
FT   VAR_SEQ     873    967       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_037957.
FT   VARIANT      35   1214       Missing (in IDDDFP).
FT                                {ECO:0000269|PubMed:27939639}.
FT                                /FTId=VAR_078076.
FT   VARIANT     370    370       P -> S (in IDDDFP; decreased histone H3-
FT                                K23 acetylation; changed cytoplasmic
FT                                localization; no effect on expression and
FT                                assembly of the MOZ/MORF complex).
FT                                {ECO:0000269|PubMed:27939640}.
FT                                /FTId=VAR_078077.
FT   VARIANT     389    389       C -> R (in IDDDFP).
FT                                {ECO:0000269|PubMed:27939639}.
FT                                /FTId=VAR_078078.
FT   VARIANT     455   1214       Missing (in IDDDFP; decreased histone H3-
FT                                K23 acetylation; increased localization
FT                                to the nucleus; decreased expression and
FT                                assembly of the MOZ/MORF complex).
FT                                {ECO:0000269|PubMed:27939640}.
FT                                /FTId=VAR_078079.
FT   VARIANT     833   1214       Missing (in IDDDFP; no effect on histone
FT                                H3-K23 acetylation; increased aggregation
FT                                in the cytoplasm; no effect on expression
FT                                and assembly of the MOZ/MORF complex).
FT                                {ECO:0000269|PubMed:27939640}.
FT                                /FTId=VAR_078080.
FT   VARIANT     988   1214       Missing (in IDDDFP).
FT                                {ECO:0000269|PubMed:27939639}.
FT                                /FTId=VAR_078081.
FT   VARIANT    1100   1214       Missing (in IDDDFP; no effect on histone
FT                                H3-K23 acetylation; no effect on
FT                                expression and assembly of the MOZ/MORF
FT                                complex). {ECO:0000269|PubMed:27939640}.
FT                                /FTId=VAR_078082.
FT   VARIANT    1117   1117       G -> E (in dbSNP:rs1042294).
FT                                /FTId=VAR_028232.
FT   VARIANT    1193   1193       H -> Q (in dbSNP:rs36081837).
FT                                /FTId=VAR_048430.
FT   CONFLICT      5      5       F -> L (in Ref. 3; BAG57257).
FT                                {ECO:0000305}.
FT   CONFLICT    299    299       A -> E (in Ref. 1; AAB02119).
FT                                {ECO:0000305}.
FT   CONFLICT    306    306       G -> D (in Ref. 3; BAG57257).
FT                                {ECO:0000305}.
FT   CONFLICT    341    341       K -> R (in Ref. 3; BAG57257).
FT                                {ECO:0000305}.
FT   CONFLICT    729    729       L -> V (in Ref. 1; AAB02119).
FT                                {ECO:0000305}.
FT   CONFLICT   1035   1035       F -> S (in Ref. 3; BAG57257).
FT                                {ECO:0000305}.
FT   TURN        277    279       {ECO:0000244|PDB:5ERC}.
FT   STRAND      286    288       {ECO:0000244|PDB:5ERC}.
FT   STRAND      290    292       {ECO:0000244|PDB:5ERC}.
FT   TURN        294    296       {ECO:0000244|PDB:5ERC}.
FT   STRAND      299    301       {ECO:0000244|PDB:5ERC}.
FT   HELIX       302    305       {ECO:0000244|PDB:5ERC}.
FT   HELIX       318    321       {ECO:0000244|PDB:5ERC}.
FT   STRAND      324    326       {ECO:0000244|PDB:5ERC}.
FT   STRAND      340    343       {ECO:0000244|PDB:5ERC}.
FT   STRAND      348    350       {ECO:0000244|PDB:5ERC}.
FT   HELIX       351    356       {ECO:0000244|PDB:5ERC}.
FT   STRAND      361    364       {ECO:0000244|PDB:5ERC}.
FT   TURN        365    368       {ECO:0000244|PDB:5ERC}.
FT   STRAND      369    372       {ECO:0000244|PDB:5ERC}.
FT   HELIX       374    376       {ECO:0000244|PDB:5ERC}.
FT   HELIX       380    383       {ECO:0000244|PDB:5ERC}.
FT   TURN        387    389       {ECO:0000244|PDB:5ERC}.
FT   STRAND      392    395       {ECO:0000244|PDB:5ERC}.
FT   HELIX       411    416       {ECO:0000244|PDB:5ERC}.
FT   STRAND      420    424       {ECO:0000244|PDB:5ERC}.
FT   STRAND      439    443       {ECO:0000244|PDB:5ERC}.
FT   HELIX       625    627       {ECO:0000244|PDB:5G4S}.
FT   HELIX       630    646       {ECO:0000244|PDB:5FFV}.
FT   STRAND      653    655       {ECO:0000244|PDB:5FFV}.
FT   TURN        659    661       {ECO:0000244|PDB:5FFV}.
FT   HELIX       665    668       {ECO:0000244|PDB:5FFV}.
FT   HELIX       675    683       {ECO:0000244|PDB:5FFV}.
FT   HELIX       690    707       {ECO:0000244|PDB:5FFV}.
FT   STRAND      710    712       {ECO:0000244|PDB:5FFW}.
FT   HELIX       713    736       {ECO:0000244|PDB:5FFV}.
FT   STRAND     1081   1083       {ECO:0000244|PDB:3L42}.
FT   STRAND     1088   1091       {ECO:0000244|PDB:3L42}.
FT   STRAND     1099   1104       {ECO:0000244|PDB:3L42}.
FT   STRAND     1113   1115       {ECO:0000244|PDB:3L42}.
FT   STRAND     1118   1120       {ECO:0000244|PDB:3L42}.
FT   HELIX      1125   1137       {ECO:0000244|PDB:3L42}.
FT   STRAND     1138   1140       {ECO:0000244|PDB:3MO8}.
FT   STRAND     1142   1149       {ECO:0000244|PDB:3L42}.
FT   STRAND     1154   1158       {ECO:0000244|PDB:3L42}.
FT   HELIX      1159   1161       {ECO:0000244|PDB:3L42}.
FT   STRAND     1162   1167       {ECO:0000244|PDB:3L42}.
FT   HELIX      1169   1176       {ECO:0000244|PDB:3L42}.
FT   HELIX      1182   1202       {ECO:0000244|PDB:3L42}.
SQ   SEQUENCE   1214 AA;  137499 MW;  618F359F21F4CBF7 CRC64;
     MGVDFDVKTF CHNLRATKPP YECPVETCRK VYKSYSGIEY HLYHYDHDNP PPPQQTPLRK
     HKKKGRQSRP ANKQSPSPSE VSQSPGREVM SYAQAQRMVE VDLHGRVHRI SIFDNLDVVS
     EDEEAPEEAP ENGSNKENTE TPAATPKSGK HKNKEKRKDS NHHHHHNVSA STTPKLPEVV
     YRELEQDTPD APPRPTSYYR YIEKSAEELD EEVEYDMDEE DYIWLDIMNE RRKTEGVSPI
     PQEIFEYLMD RLEKESYFES HNKGDPNALV DEDAVCCICN DGECQNSNVI LFCDMCNLAV
     HQECYGVPYI PEGQWLCRRC LQSPSRAVDC ALCPNKGGAF KQTDDGRWAH VVCALWIPEV
     CFANTVFLEP IDSIEHIPPA RWKLTCYICK QRGSGACIQC HKANCYTAFH VTCAQQAGLY
     MKMEPVRETG ANGTSFSVRK TAYCDIHTPP GSARRLPALS HSEGEEDEDE EEDEGKGWSS
     EKVKKAKAKS RIKMKKARKI LAEKRAAAPV VSVPCIPPHR LSKITNRLTI QRKSQFMQRL
     HSYWTLKRQS RNGVPLLRRL QTHLQSQRNC DQVGRDSEDK NWALKEQLKS WQRLRHDLER
     ARLLVELIRK REKLKRETIK VQQIAMEMQL TPFLILLRKT LEQLQEKDTG NIFSEPVPLS
     EVPDYLDHIK KPMDFFTMKQ NLEAYRYLNF DDFEEDFNLI VSNCLKYNAK DTIFYRAAVR
     LREQGGAVLR QARRQAEKMG IDFETGMHIP HSLAGDEATH HTEDAAEEER LVLLENQKHL
     PVEEQLKLLL ERLDEVNASK QSVGRSRRAK MIKKEMTALR RKLAHQRETG RDGPERHGPS
     SRGSLTPHPA ACDKDGQTDS AAEESSSQET SKGLGPNMSS TPAHEVGRRT SVLFSKKNPK
     TAGPPKRPGR PPKNRESQMT PSHGGSPVGP PQLPIMSSLR QRKRGRSPRP SSSSDSDSDK
     STEDPPMDLP ANGFSGGNQP VKKSFLVYRN DCSLPRSSSD SESSSSSSSS AASDRTSTTP
     SKQGRGKPSF SRGTFPEDSS EDTSGTENEA YSVGTGRGVG HSMVRKSLGR GAGWLSEDED
     SPLDALDLVW AKCRGYPSYP ALIIDPKMPR EGMFHHGVPI PVPPLEVLKL GEQMTQEARE
     HLYLVLFFDN KRTWQWLPRT KLVPLGVNQD LDKEKMLEGR KSNIRKSVQI AYHRALQHRS
     KVQGEQSSET SDSD
//
